Home

– About Artemis –

Artemis Therapeutics, Inc. (ATMS) is a biopharmaceutical company developing novel treatments for serious and life-threatening infections. The company’s lead drug candidate, Artemisone, is a best-in-class artemisinin which has been studied in a phase 2 clinical trial for the treatment of malaria (p. falciparum) and is currently undergoing in vitro evaluation for its activity against human cytomegalovirus (CMV), including transplant CMV and congenital CMV.

– PIPELINE –

Artemisone: Multiple Potential Indications

Pre-Clinical
Phase 1
Phase 2
Phase 3

Treatment of p.falciparum Malaria

Treatment of CMV in HCT

Treatment of CMV in SOT

Treatment of Congenital CMV in Neonates

  • Other potential anti-parasitic and anti-viral indications being explored in pre-clinical testing
  • Two additional programs to be named 1H2018